eMed
eMed is a Miami-based telehealth AI company that delivers employer-sponsored GLP-1 weight management with at-home biomarker screening, guaranteed outcomes, and pharmacy integration for enterprise and healthcare-worker clients.
- Company typePrivate
- Founded2020
- HeadquartersMiami, United States
- Headcount101–250
- GTM typeB2B and B2C
- OfferingServices
What eMed does
eMed is a Miami-headquartered telehealth company that pivoted from COVID-19 testing services (founded 2020) into an AI-enabled GLP-1 weight-management platform. Its core offering combines at-home biomarker screening (HbA1c, Creatinine, hs-CRP, GGT, Lipid Panel, Vitamin B12), an "agentic AI" adherence and outcomes layer, and guaranteed clinical results (>90% adherence, 14.2-month average duration, -25 lbs average weight loss, per internal Corporate Partner Data as of December 2025) into a single employer-channel product. The platform also extends into decentralized clinical-trial operations following the acquisition of Science 37.
The business operates a B2B2C model priced at $25 per covered life per month for employer sponsors and $99 per month for individual subscribers, with distribution anchored by named enterprise customers including TIAA, Lennar, AON, and CVS Health. In April 2026 the company launched a healthcare-worker program targeting 22 million US workers, and it maintains dual partnerships with Eli Lilly (Lilly Employer Connect) and Novo Nordisk (Novocare), alongside Cost Plus Drugs for pharmacy fulfillment. Operations are cited in both the US and UK.
The company employs 101-250 staff and is led by CEO Linda Yaccarino (formerly of X) with Tom Brady serving as Founding Chief Wellness Officer and co-owner. In March 2026 it closed a $200 million Series A at a $2 billion-plus valuation led by AON Consulting, which is also an employer customer, indicating a tightly aligned investor-distribution relationship.
eMed firmographics
Firmographics- Name
- eMed
- Legal name
- eMed
- Website
- https://emed.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- eMed is a Miami-based telehealth AI company that delivers employer-sponsored GLP-1 weight management with at-home biomarker screening, guaranteed outcomes, and pharmacy integration for enterprise and healthcare-worker clients.
- Ownership category
- akta.pro rank
eMed industry classification
Industry- Product category
- Digital Health / Telehealth Weight Management
- NAICS
- Diet and Weight Reducing Centers (812191)
- SIC
- Services-Health Services (8000), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing (HLALAIAH)
- akta.pro secondary industries
- Medication Adherence & Therapy Management Platforms (refills, reminders, MTM) (HLALAIAG), Medication Pricing, Copay Assistance & Patient Financial Support Tools (HLACAKAN)
Keywords
Where eMed is headquartered
LocationHeadquarters
- HQ city
- Miami
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
eMed business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
Revenue model
- Capitated Employer Healthcare Plans: eMed operates a capitated flat-fee model where employers pay a fixed monthly amount per covered employee ($25 per covered life per month for healthcare worker programs), enabling predictable healthcare cost budgeting and reducing exposure to GLP-1 medication price volatility and PBM markups.
- Individual Program Fees (Healthcare Worker Exclusive): Enrolled employees pay $99 per month for all clinical services and FDA-approved GLP-1 medications as part of the exclusive healthcare worker program. This individual subscription supplements employer capitated revenue.
- Pharmacy/Medication Fulfillment: Revenue from supplying GLP-1 medications (Wegovy, Zepbound) to members through partnerships with Novo Nordisk and Eli Lilly, integrated into the employer platform and individual programs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Healthcare Worker Employer Plan — $25 per covered life/month (employer pays) |
| Per seat | Monthly | Individual Healthcare Worker Member — $99/month |
| Subscription | Annual | Employer GLP-1 Platform (General) — Quote-based |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels5 records
eMed product offering
Product offeringCore offering
eMed operates a weight management and population health platform combining a clinically supervised GLP-1 medication program, at-home biomarker diagnostic screening, and a mobile app with 24/7 clinical support and continuous adherence monitoring. For employers, it delivers the offering under a capitated flat-fee payment model with no PBM markups and guaranteed adherence and weight-loss outcomes. For individuals, the same platform is accessed via a direct-to-consumer mobile app subscription.
Product overview
eMed operates as a unified Weight Management and Population Health Platform combining three core components: (1) a clinically supervised GLP-1 Program for weight management and chronic disease care, (2) an At Home Screening Kit for clinical biomarker assessment, and (3) an Agentic AI Platform for employer healthcare cost optimization. The platform also includes a mobile app (eMed Population Health App) available on iOS and Android, and operates under a capitated care model for employers. The company expanded through acquisition of Science 37 to integrate decentralized clinical trials. The platform is designed to maximize adherence and bend employer healthcare cost curves through integrated diagnostics, clinical support, and AI-driven cost management.
Differentiator
Problem solved
Functional benefit
Products and services
- GLP-1 Program Clinically supervised GLP-1 weight management program for employers and individuals featuring 24/7 clinical support, personalized guidance, and continuous adherence monitoring; reports over 90% member adherence and average weight loss of 25 lbs.
- At Home Screening Kit Clinical intake diagnostic kit that screens for key biomarkers including HbA1C, Creatinine, hs-CRP, GGT, Lipid Panel, and Vitamin B12 to assess metabolic health and cardiovascular risk, used as the clinical on-ramp for eMed's GLP-1 program.
- eMed Population Health Mobile App Mobile application for iOS and Android that delivers 24/7 clinical support, personalized guidance, continuous adherence monitoring, and access to GLP-1 programs and at-home diagnostic services for individual members.
- Science 37 Decentralized Clinical Trials Platform Decentralized clinical trials platform acquired by eMed that enables remote, at-home clinical study participation and strengthens the company's clinical evidence generation capabilities.
Quantifiable outcome
- 90%+ GLP-1 program member adherence rate, more than double the industry norm
- +7 more outcomes
Companies that use eMed
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
eMed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature4 records
eMed partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Novo NordiskcoreeMed was named a Novocare Recognized Care Provider by Novo Nordisk in January 2026, enabling eMed to deliver access to the newly FDA-approved Wegovy oral semaglutide pill (approved December 2025) — the first and only oral GLP-1 medication for chronic weight management. The partnership combines Novo Nordisk's pharmaceutical products with eMed's clinically guided care model for adherence support and long-term engagement. Novo Nordisk's clinical data showed approximately 17% average weight loss with Wegovy pill.
- Mark Cuban Cost Plus Drug CompanycoreeMed and Mark Cuban's Cost Plus Drugs announced a collaboration at SXSW 2026, under which eMed's employer customers have their GLP-1 medication needs fulfilled through Cost Plus Drugs at the lowest possible prices. Both companies positioned the partnership as aligned in 'fighting for the lowest price possible' for employers and patients, differentiating from direct-to-consumer competitors.
- Eli Lilly (Employer Connect Platform)coreeMed is listed as one of over 15 independent program administrators on Eli Lilly's Employer Connect platform, launched March 5, 2026. The platform provides Zepbound KwikPen at $449/dose across all strengths, enabling eMed to offer Lilly's GLP-1 medications to its employer customers through a structured, discounted pricing channel outside traditional PBM models.
- Science 37minoreMed acquired Science 37 to integrate decentralized clinical trial capabilities into its digital health platform. This acquisition expands eMed's clinical evidence generation capabilities and enables remote, at-home clinical study participation for members, differentiating its platform with research-grade data and evidence.
Scale indicators13 records
Recent moves6 records
Expansion highlights6 records
eMed competitors and assessment
Company assessmentDirect peers
- Hims & Hers Health: Hims & Hers is a leading DTC telehealth platform that has expanded aggressively into GLP-1 weight-loss programs. Directly competes with eMed in the consumer-facing GLP-1 channel and serves as the primary benchmark cited for churn rates.
- Ro: Ro operates a vertically integrated telehealth platform offering GLP-1 weight management alongside men's and women's health. Direct competitor to eMed in DTC GLP-1s and frequently cited by eMed leadership as the comparison point.
- Found: Found is a weight-management program combining clinician-supervised care with medication (including GLP-1s) and behavior coaching. Highly comparable to eMed on the clinical-supervision-plus-medication model for chronic weight management.
- Calibrate: Calibrate offers a metabolic-health weight-loss program combining GLP-1 medication with coaching and clinician oversight. Comparable to eMed in combining medication management with longitudinal coaching and outcomes tracking.
- LifeMD: LifeMD is a telehealth company offering weight-management programs including GLP-1s, with employer and direct-to-consumer channels. Comparable to eMed in combining virtual clinical care, prescription medication, and DTC/employer distribution.
- WeightWatchers (WW): WW has pivoted from pure behavior-based weight loss into a clinician-supervised program that includes access to GLP-1 medications. Comparable to eMed in weight-management outcomes focus and employer channel ambitions.
- Noom: Noom is a digital weight-management platform combining behavior change, coaching, and increasingly clinician-supervised medication including GLP-1s. Comparable to eMed on chronic weight-management outcomes, adherence focus, and employer/B2B distribution.
Emerging players
- Virta Health: Virta Health delivers digitally enabled chronic-disease reversal programs, with strong evidence in type-2 diabetes and prediabetes. Comparable to eMed in the cardiometabolic, biomarker-driven chronic-disease management space that eMed is expanding into.
- Omada Health: Omada Health is a digital chronic-disease prevention and management platform sold primarily to employers and health plans, with focus on diabetes, hypertension, and behavioral health. Comparable to eMed on employer-B2B chronic-disease distribution.
Broad incumbents
- Teladoc Health: Teladoc Health is a large incumbent in virtual care with employer and health-plan channels across primary care, mental health, and chronic conditions. Comparable to eMed in employer-B2B distribution and chronic-condition management, though not GLP-1-specialized.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
eMed social profiles
Digital presenceeMed financial estimates
Financial estimateRevenue estimate
Valuation estimate
eMed leadership team
Management profileNumber of profiles
Profiles2 records
eMed subsidiaries and ownership
Company hierarchySubsidiaries1 record
eMed funding detail
Funding detailFunding overview
Funding rounds5 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
eMed M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about eMed
What does eMed do?
eMed operates a weight management and population health platform combining a clinically supervised GLP-1 medication program, at-home biomarker diagnostic screening, and a mobile app with 24/7 clinical support and continuous adherence monitoring. For employers, it delivers the offering under a capitated flat-fee payment model with no PBM markups and guaranteed adherence and weight-loss outcomes. For individuals, the same platform is accessed via a direct-to-consumer mobile app subscription.
Is eMed a public or private company?
eMed is a private company. It is classified as venture growth investor backed and is currently operating.
When was eMed founded?
eMed was founded in 2020. It employs 101 to 250 people.
Where is eMed based?
eMed is headquartered in Miami, United States, in the North America region.
How does eMed make money?
Three revenue lines are on record. Capitated Employer Healthcare Plans are the primary driver. The others are individual Program Fees (Healthcare Worker Exclusive) and pharmacy/Medication Fulfillment.
Who are eMed's main competitors?
Direct peers on record are Hims & Hers Health, Ro, Found, Calibrate, LifeMD, WeightWatchers (WW) and Noom. Emerging players are Virta Health and Omada Health. Teladoc Health is listed as a broad incumbent.
Does eMed have an API?
No public API is recorded for eMed.
What industry is eMed in?
eMed's product category is Digital Health / Telehealth Weight Management. Its primary akta.pro industry code is HLALAIAH, Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing, with a secondary code of HLALAIAG, Medication Adherence & Therapy Management Platforms (refills, reminders, MTM). Its NAICS code is 812191 and its SIC code is 8000.